Myriad Announces New Laboratory Agreement with Pfizer®

Author's Avatar
Oct 10, 2018
Article's Main Image

Myriad to Provide BRACAnalysis CDx Testing in a Phase 2 Study Evaluating Talazoparib for Neo-adjuvant Treatment of Germline BRCA-mutated Triple Negative Breast Cancer